Synaptogenix, Inc. (SNPX)

4.7100 0.0000 (0.00%) As of 11:03AM EDT. Market open.

Synaptogenix, Inc.

1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
973 242 0005
https://www.synaptogen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Alan J. Tuchman M.D., MBA(FAAN)	CEO & Director	303.35k	N/A	1947
Dr. Daniel L. Alkon M.D.	President, Chief Scientific Officer & Director	375k	N/A	1942
Mr. Robert Weinstein	CFO, Executive VP, Treasurer & Secretary	568.92k	N/A	1960

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Corporate governance

Synaptogenix, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.